Summary
This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for each of these cancer types, and features dormant and discontinued projects.
Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. There are a total of 322 products in development for this indication, by 208 companies and 22 academic institutions. Key companies operating in this pipeline space include Eli Lilly, Roche, Bristol-Myers Squibb, Incyte, Pfizer and AstraZeneca.
Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. There are a total of 107 products in development for this indication, by 79 companies and 11 academic institutions.
Key targets in development across both indications include human epidermal growth factors 1 and 2, and programmed cell death protein 1. In addition, the hepatocyte and vascular endothelial growth factors are being developed across many pipeline programs in gastric cancer.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
'
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 9
2 Introduction 10
2.1 Gastric and Esophageal Cancer Report Coverage 10
2.2 Esophageal Cancer – Overview 10
2.3 Gastric Cancer – Overview 10
3 Therapeutics Development 11
3.1 Esophageal Cancer 11
3.2 Gastric Cancer 21
4 Therapeutics Assessment 45
4.1 Esophageal Cancer 45
4.2 Gastric Cancer 56
5 Companies Involved in Therapeutics Development 78
5.1 Esophageal Cancer 78
5.2 Gastric Cancer 109
6 Dormant Projects 187
6.1 Esophageal Cancer 187
6.2 Gastric Cancer 190
7 Discontinued Products 198
7.1 Esophageal Cancer 198
7.2 Gastric Cancer 199
8 Product Development Milestones 202
8.1 Esophageal Cancer 202
8.2 Gastric Cancer 218
9 Appendix 243
9.1 Methodology 243
9.2 Coverage 243
9.3 Secondary Research 243
9.4 Primary Research 243
9.5 Expert Panel Validation 243
9.6 Contact Us 244
9.7 Disclaimer 244
1.1 List of Tables
Table 1: Number of Products under Development for Esophageal Cancer 11
Table 2: Number of Products under Development by Companies, Esophageal Cancer 13
Table 3: Number of Products under Development by Universities/Institutes, Esophageal Cancer 15
Table 4: Products under Development by Companies, Esophageal Cancer 16
Table 5: Products under Development by Universities/Institutes, Esophageal Cancer 20
Table 6: Number of Products under Development for Gastric Cancer 21
Table 7: Number of Products under Development by Companies, Gastric Cancer 23
Table 8: Number of Products under Development by Universities/Institutes, Gastric Cancer 30
Table 9: Products under Development by Companies, Gastric Cancer 31
Table 10: Products under Development by Universities/Institutes, Gastric Cancer 43
Table 11: Number of Products by Stage and Target, Esophageal Cancer 46
Table 12: Number of Products by Stage and Mechanism of Action, Esophageal Cancer 50
Table 13: Number of Products by Stage and Route of Administration, Esophageal Cancer 54
Table 14: Number of Products by Stage and Molecule Type, Esophageal Cancer 56
Table 15: Number of Products by Stage and Target, Gastric Cancer 58
Table 16: Number of Products by Stage and Mechanism of Action, Gastric Cancer 66
Table 17: Number of Products by Stage and Route of Administration, Gastric Cancer 75
Table 18: Number of Products by Stage and Molecule Type, Gastric Cancer 77
Table 19: Esophageal Cancer – Pipeline by Adaptimmune Therapeutics Plc 78
Table 20: Esophageal Cancer – Pipeline by ADC Therapeutics Sarl 78
Table 21: Esophageal Cancer – Pipeline by Aduro BioTech Inc 79
Table 22: Esophageal Cancer – Pipeline by Advenchen Laboratories LLC 79
Table 23: Esophageal Cancer – Pipeline by Almac Discovery Ltd 80
Table 24: Esophageal Cancer – Pipeline by Ambrx Inc 80
Table 25: Esophageal Cancer – Pipeline by Amgen Inc 81
Table 26: Esophageal Cancer – Pipeline by Aprea AB 81
Table 27: Esophageal Cancer – Pipeline by ArQule Inc 82
Table 28: Esophageal Cancer – Pipeline by Array BioPharma Inc 82
Table 29: Esophageal Cancer – Pipeline by Aslan Pharmaceuticals Pte Ltd 83
Table 30: Esophageal Cancer – Pipeline by Bayer AG 83
Table 31: Esophageal Cancer – Pipeline by BeiGene Ltd 84
Table 32: Esophageal Cancer – Pipeline by BioStar Pharmaceuticals Inc 84
Table 33: Esophageal Cancer – Pipeline by Boehringer Ingelheim GmbH 85
Table 34: Esophageal Cancer – Pipeline by Bristol-Myers Squibb Co 85
Table 35: Esophageal Cancer – Pipeline by Cascadian Therapeutics Inc 86
Table 36: Esophageal Cancer – Pipeline by CBT Pharmaceuticals Inc 86
Table 37: Esophageal Cancer – Pipeline by Celgene Corp 87
Table 38: Esophageal Cancer – Pipeline by Celldex Therapeutics Inc 87
Table 39: Esophageal Cancer – Pipeline by Cellectar Biosciences Inc 88
Table 40: Esophageal Cancer – Pipeline by Clovis Oncology Inc 88
Table 41: Esophageal Cancer – Pipeline by Cyclacel Pharmaceuticals Inc 89
Table 42: Esophageal Cancer – Pipeline by DAE HWA Pharmaceutical Co Ltd 89
Table 43: Esophageal Cancer – Pipeline by Eli Lilly and Co 90
Table 44: Esophageal Cancer – Pipeline by F. Hoffmann-La Roche Ltd 90
Table 45: Esophageal Cancer – Pipeline by Genmab A/S 91
Table 46: Esophageal Cancer – Pipeline by GlaxoSmithKline Plc 92
Table 47: Esophageal Cancer – Pipeline by Glycotope GmbH 92
Table 48: Esophageal Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd 92
Table 49: Esophageal Cancer – Pipeline by Hutchison MediPharma Ltd 93
Table 50: Esophageal Cancer – Pipeline by Ignyta Inc 93
Table 51: Esophageal Cancer – Pipeline by Immunocore Ltd 94
Table 52: Esophageal Cancer – Pipeline by ImmunoFrontier Inc 94
Table 53: Esophageal Cancer – Pipeline by Immunomedics Inc 95
Table 54: Esophageal Cancer – Pipeline by Incyte Corp 95
Table 55: Esophageal Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd 96
Table 56: Esophageal Cancer – Pipeline by Johnson & Johnson 96
Table 57: Esophageal Cancer – Pipeline by Leap Therapeutics Inc 97
Table 58: Esophageal Cancer – Pipeline by Madrigal Pharmaceuticals Inc. 97
Table 59: Esophageal Cancer – Pipeline by MaxiVAX SA 98
Table 60: Esophageal Cancer – Pipeline by Mebiopharm Co Ltd 98
Table 61: Esophageal Cancer – Pipeline by MedImmune LLC 99
Table 62: Esophageal Cancer – Pipeline by Merck & Co Inc 99
Table 63: Esophageal Cancer – Pipeline by Merrimack Pharmaceuticals Inc 100
Table 64: Esophageal Cancer – Pipeline by Novartis AG 100
Table 65: Esophageal Cancer – Pipeline by Omeros Corp 101
Table 66: Esophageal Cancer – Pipeline by Omnitura Therapeutics Inc 101
Table 67: Esophageal Cancer – Pipeline by Oncolys BioPharma Inc 102
Table 68: Esophageal Cancer – Pipeline by Ono Pharmaceutical Co Ltd 103
Table 69: Esophageal Cancer – Pipeline by Puma Biotechnology Inc 103
Table 70: Esophageal Cancer – Pipeline by Rhizen Pharmaceuticals SA 103
Table 71: Esophageal Cancer – Pipeline by Shionogi & Co Ltd 104
Table 72: Esophageal Cancer – Pipeline by Spectrum Pharmaceuticals Inc 104
Table 73: Esophageal Cancer – Pipeline by Steba Biotech SA 105
Table 74: Esophageal Cancer – Pipeline by Stelic Institute & Co Inc 105
Table 75: Esophageal Cancer – Pipeline by Supratek Pharma Inc 106
Table 76: Esophageal Cancer – Pipeline by Symphogen A/S 106
Table 77: Esophageal Cancer – Pipeline by Taiho Pharmaceutical Co Ltd 106
Table 78: Esophageal Cancer – Pipeline by Taiwan Liposome Company Ltd 107
Table 79: Esophageal Cancer – Pipeline by Takara Bio Inc 107
Table 80: Esophageal Cancer – Pipeline by Transgene Biotek Ltd 108
Table 81: Esophageal Cancer – Pipeline by XuanZhu Pharma Co Ltd 108
Table 82: Gastric Cancer – Pipeline by 3SBio Inc 109
Table 83: Gastric Cancer – Pipeline by AbbVie Inc 110
Table 84: Gastric Cancer – Pipeline by AbGenomics International Inc 110
Table 85: Gastric Cancer – Pipeline by Abion Inc 111
Table 86: Gastric Cancer – Pipeline by Adaptimmune Therapeutics Plc 111
Table 87: Gastric Cancer – Pipeline by ADC Therapeutics Sarl 111
Table 88: Gastric Cancer – Pipeline by Aduro BioTech Inc 112
Table 89: Gastric Cancer – Pipeline by Advenchen Laboratories LLC 112
Table 90: Gastric Cancer – Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd 113
Table 91: Gastric Cancer – Pipeline by Almac Discovery Ltd 113
Table 92: Gastric Cancer – Pipeline by Alteogen Inc 114
Table 93: Gastric Cancer – Pipeline by Ambrx Inc 114
Table 94: Gastric Cancer – Pipeline by amcure GmbH 115
Table 95: Gastric Cancer – Pipeline by Amgen Inc 115
Table 96: Gastric Cancer – Pipeline by ANP Technologies Inc 116
Table 97: Gastric Cancer – Pipeline by Antikor Biopharma Ltd 116
Table 98: Gastric Cancer – Pipeline by arGEN-X BV 117
Table 99: Gastric Cancer – Pipeline by Array BioPharma Inc 117
Table 100: Gastric Cancer – Pipeline by Asana BioSciences LLC 118
Table 101: Gastric Cancer – Pipeline by Aslan Pharmaceuticals Pte Ltd 118
Table 102: Gastric Cancer – Pipeline by Astellas Pharma Inc 119
Table 103: Gastric Cancer – Pipeline by AstraZeneca Plc 120
Table 104: Gastric Cancer – Pipeline by Athenex Inc 120
Table 105: Gastric Cancer – Pipeline by Basilea Pharmaceutica Ltd 120
Table 106: Gastric Cancer – Pipeline by Bayer AG 121
Table 107: Gastric Cancer – Pipeline by BeiGene Ltd 122
Table 108: Gastric Cancer – Pipeline by Beijing Hanmi Pharmaceutical Co Ltd 122
Table 109: Gastric Cancer – Pipeline by Betta Pharmaceuticals Co Ltd 123
Table 110: Gastric Cancer – Pipeline by Biocon Ltd 123
Table 111: Gastric Cancer – Pipeline by Bioleaders Corp 123
Table 112: Gastric Cancer – Pipeline by Bionovis SA 124
Table 113: Gastric Cancer – Pipeline by Boehringer Ingelheim GmbH 124
Table 114: Gastric Cancer – Pipeline by Bristol-Myers Squibb Co 125
Table 115: Gastric Cancer – Pipeline by Camel-IDS NV 126
Table 116: Gastric Cancer – Pipeline by Cancer Prevention Pharmaceuticals Inc 126
Table 117: Gastric Cancer – Pipeline by Cascadian Therapeutics Inc 126
Table 118: Gastric Cancer – Pipeline by CBT Pharmaceuticals Inc 127
Table 119: Gastric Cancer – Pipeline by Celgene Corp 127
Table 120: Gastric Cancer – Pipeline by Celldex Therapeutics Inc 128
Table 121: Gastric Cancer – Pipeline by Cellectar Biosciences Inc 129
Table 122: Gastric Cancer – Pipeline by Celltrion Inc 129
Table 123: Gastric Cancer – Pipeline by Celon Pharma SA 130
Table 124: Gastric Cancer – Pipeline by Chipscreen Biosciences Ltd 130
Table 125: Gastric Cancer – Pipeline by Chugai Pharmaceutical Co Ltd 131
Table 126: Gastric Cancer – Pipeline by Curaxys SL 131
Table 127: Gastric Cancer – Pipeline by Cytori Therapeutics Inc 132
Table 128: Gastric Cancer – Pipeline by Daiichi Sankyo Co Ltd 132
Table 129: Gastric Cancer – Pipeline by Debiopharm International SA 133
Table 130: Gastric Cancer – Pipeline by Deciphera Pharmaceuticals LLC 133
Table 131: Gastric Cancer – Pipeline by Dr. Reddy's Laboratories Ltd 134
Table 132: Gastric Cancer – Pipeline by Eddingpharm Inc 134
Table 133: Gastric Cancer – Pipeline by Eli Lilly and Co 135
Table 134: Gastric Cancer – Pipeline by EOS Biosciences Inc 136
Table 135: Gastric Cancer – Pipeline by Erytech Pharma SA 136
Table 136: Gastric Cancer – Pipeline by Esperance Pharmaceuticals Inc 136
Table 137: Gastric Cancer – Pipeline by Exelixis Inc 137
Table 138: Gastric Cancer – Pipeline by F-star Biotechnology Ltd 137
Table 139: Gastric Cancer – Pipeline by F. Hoffmann-La Roche Ltd 138
Table 140: Gastric Cancer – Pipeline by Five Prime Therapeutics Inc 139
Table 141: Gastric Cancer – Pipeline by Frost Biologic Inc 139
Table 142: Gastric Cancer – Pipeline by Galena Biopharma Inc 140
Table 143: Gastric Cancer – Pipeline by Genelux Corp 140
Table 144: Gastric Cancer – Pipeline by Genentech Inc 140
Table 145: Gastric Cancer – Pipeline by Gilead Sciences Inc 141
Table 146: Gastric Cancer – Pipeline by GlaxoSmithKline Plc 142
Table 147: Gastric Cancer – Pipeline by Glenmark Pharmaceuticals Ltd 142
Table 148: Gastric Cancer – Pipeline by GlycoNex Inc 143
Table 149: Gastric Cancer – Pipeline by Glycotope GmbH 143
Table 150: Gastric Cancer – Pipeline by Green Cross Corp 144
Table 151: Gastric Cancer – Pipeline by Halozyme Therapeutics Inc 144
Table 152: Gastric Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd 145
Table 153: Gastric Cancer – Pipeline by Horizon Pharma Plc 145
Table 154: Gastric Cancer – Pipeline by Humanigen Inc 146
Table 155: Gastric Cancer – Pipeline by Hummingbird Bioscience Pte Ltd 146
Table 156: Gastric Cancer – Pipeline by Hutchison MediPharma Ltd 147
Table 157: Gastric Cancer – Pipeline by Ignyta Inc 147
Table 158: Gastric Cancer – Pipeline by Ildong Pharmaceutical Co Ltd 148
Table 159: Gastric Cancer – Pipeline by Immunomedics Inc 149
Table 160: Gastric Cancer – Pipeline by Incyte Corp 149
Table 161: Gastric Cancer – Pipeline by Inovio Pharmaceuticals Inc 150
Table 162: Gastric Cancer – Pipeline by Inspyr Therapeutics Inc 150
Table 163: Gastric Cancer – Pipeline by Insys Therapeutics Inc 151
Table 164: Gastric Cancer – Pipeline by Ipsen SA 151
Table 165: Gastric Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd 152
Table 166: Gastric Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd 153
Table 167: Gastric Cancer – Pipeline by Johnson & Johnson 153
Table 168: Gastric Cancer – Pipeline by Jounce Therapeutics Inc 154
Table 169: Gastric Cancer – Pipeline by Konruns Pharmaceutical Co Ltd 154
Table 170: Gastric Cancer – Pipeline by Kringle Pharma Inc 155
Table 171: Gastric Cancer – Pipeline by Kuhnil Pharmaceutical Co Ltd 155
Table 172: Gastric Cancer – Pipeline by Kyowa Hakko Kirin Co Ltd 156
Table 173: Gastric Cancer – Pipeline by LATITUDE Pharmaceuticals Inc 156
Table 174: Gastric Cancer – Pipeline by LegoChem Biosciences Inc 157
Table 175: Gastric Cancer – Pipeline by LinXis BV 157
Table 176: Gastric Cancer – Pipeline by MacroGenics Inc 158
Table 177: Gastric Cancer – Pipeline by Madrigal Pharmaceuticals Inc. 158
Table 178: Gastric Cancer – Pipeline by MaxiVAX SA 158
Table 179: Gastric Cancer – Pipeline by Mebiopharm Co Ltd 159
Table 180: Gastric Cancer – Pipeline by MedImmune LLC 159
Table 181: Gastric Cancer – Pipeline by Merck & Co Inc 160
Table 182: Gastric Cancer – Pipeline by Merck KGaA 160
Table 183: Gastric Cancer – Pipeline by Merrimack Pharmaceuticals Inc 161
Table 184: Gastric Cancer – Pipeline by Mersana Therapeutics Inc 161
Table 185: Gastric Cancer – Pipeline by Merus NV 162
Table 186: Gastric Cancer – Pipeline by Mirati Therapeutics Inc 162
Table 187: Gastric Cancer – Pipeline by Molecular Partners AG 163
Table 188: Gastric Cancer – Pipeline by Molecular Targeting Technologies Inc 163
Table 189: Gastric Cancer – Pipeline by Moleculin Biotech Inc 164
Table 190: Gastric Cancer – Pipeline by MolMed SpA 164
Table 191: Gastric Cancer – Pipeline by NanoCarrier Co Ltd 165
Table 192: Gastric Cancer – Pipeline by Novartis AG 166
Table 193: Gastric Cancer – Pipeline by Novogen Ltd 166
Table 194: Gastric Cancer – Pipeline by OBI Pharma Inc 167
Table 195: Gastric Cancer – Pipeline by Oncobiologics Inc 167
Table 196: Gastric Cancer – Pipeline by Oncolys BioPharma Inc 168
Table 197: Gastric Cancer – Pipeline by OncoMed Pharmaceuticals Inc 168
Table 198: Gastric Cancer – Pipeline by OncoResponse Inc 169
Table 199: Gastric Cancer – Pipeline by Ono Pharmaceutical Co Ltd 169
Table 200: Gastric Cancer – Pipeline by Opsona Therapeutics Ltd 170
Table 201: Gastric Cancer – Pipeline by Patrys Ltd 170
Table 202: Gastric Cancer – Pipeline by Pfizer Inc 171
Table 203: Gastric Cancer – Pipeline by Pharma Mar SA 171
Table 204: Gastric Cancer – Pipeline by Pieris Pharmaceuticals Inc 172
Table 205: Gastric Cancer – Pipeline by Plexxikon Inc 172
Table 206: Gastric Cancer – Pipeline by Prescient Therapeutics Ltd 173
Table 207: Gastric Cancer – Pipeline by Puma Biotechnology Inc 173
Table 208: Gastric Cancer – Pipeline by Redx Pharma Plc 173
Table 209: Gastric Cancer – Pipeline by Rhizen Pharmaceuticals SA 174
Table 210: Gastric Cancer – Pipeline by Richter Gedeon Nyrt 174
Table 211: Gastric Cancer – Pipeline by Samumed LLC 175
Table 212: Gastric Cancer – Pipeline by Sanofi 175
Table 213: Gastric Cancer – Pipeline by Selecta Biosciences Inc 176
Table 214: Gastric Cancer – Pipeline by Sequella Inc 176
Table 215: Gastric Cancer – Pipeline by Shionogi & Co Ltd 177
Table 216: Gastric Cancer – Pipeline by Simcere Pharmaceutical Group 177
Table 217: Gastric Cancer – Pipeline by Sorrento Therapeutics Inc 178
Table 218: Gastric Cancer – Pipeline by Spectrum Pharmaceuticals Inc 178
Table 219: Gastric Cancer – Pipeline by Stelic Institute & Co Inc 179
Table 220: Gastric Cancer – Pipeline by Supratek Pharma Inc 179
Table 221: Gastric Cancer – Pipeline by SynCore Biotechnology Co Ltd 180
Table 222: Gastric Cancer – Pipeline by Synovo GmbH 180
Table 223: Gastric Cancer – Pipeline by Synthon Holdings BV 180
Table 224: Gastric Cancer – Pipeline by Taiho Pharmaceutical Co Ltd 181
Table 225: Gastric Cancer – Pipeline by Taiwan Liposome Company Ltd 182
Table 226: Gastric Cancer – Pipeline by Takis Srl 182
Table 227: Gastric Cancer – Pipeline by Tessa Therapeutics Pte Ltd 182
Table 228: Gastric Cancer – Pipeline by Transgene SA 183
Table 229: Gastric Cancer – Pipeline by Tyrogenex Inc 183
Table 230: Gastric Cancer – Pipeline by United BioPharma Inc 184
Table 231: Gastric Cancer – Pipeline by Vaxon Biotech 184
Table 232: Gastric Cancer – Pipeline by ViiV Healthcare Ltd 184
Table 233: Gastric Cancer – Pipeline by Viracta Therapeutics Inc 185
Table 234: Gastric Cancer – Pipeline by XuanZhu Pharma Co Ltd 185
Table 235: Gastric Cancer – Pipeline by Zymeworks Inc 186
Table 236: Esophageal Cancer – Dormant Projects 187
Table 237: Gastric Cancer – Dormant Projects 190
Table 238: Esophageal Cancer – Discontinued Products 198
Table 239: Gastric Cancer – Discontinued Products 199
1.2 List of Figures
Figure 1: Number of Products under Development for Esophageal Cancer 11
Figure 2: Number of Products under Development by Companies, Esophageal Cancer 12
Figure 3: Number of Products under Development by Universities/Institutes, Esophageal Cancer 15
Figure 4: Number of Products under Development for Gastric Cancer 21
Figure 5: Number of Products under Development by Companies, Gastric Cancer 22
Figure 6: Number of Products under Development by Universities/Institutes, Gastric Cancer 29
Figure 7: Number of Products by Top 10 Targets, Esophageal Cancer 45
Figure 8: Number of Products by Stage and Top 10 Targets, Esophageal Cancer 45
Figure 9: Number of Products by Top 10 Mechanism of Actions, Esophageal Cancer 49
Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions, Esophageal Cancer 49
Figure 11: Number of Products by Top 10 Routes of Administration, Esophageal Cancer 53
Figure 12: Number of Products by Stage and Top 10 Routes of Administration, Esophageal Cancer 53
Figure 13: Number of Products by Top 10 Molecule Types, Esophageal Cancer 55
Figure 14: Number of Products by Stage and Top 10 Molecule Types, Esophageal Cancer 55
Figure 15: Number of Products by Top 10 Targets, Gastric Cancer 56
Figure 16: Number of Products by Stage and Top 10 Targets, Gastric Cancer 57
Figure 17: Number of Products by Top 10 Mechanism of Actions, Gastric Cancer 64
Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Gastric Cancer 65
Figure 19: Number of Products by Routes of Administration, Gastric Cancer 74
Figure 20: Number of Products by Stage and Routes of Administration, Gastric Cancer 75
Figure 21: Number of Products by Top 10 Molecule Types, Gastric Cancer 76
Figure 22: Number of Products by Stage and Top 10 Molecule Types, Gastric Cancer 76
